使用贝曲西利（KM2210）治疗复发性乳腺癌的疗效
[Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
作者信息
Ueda T, Sakai K, Morimoto K, Nakatani S
机构信息
Second Dept. of Surgery, Osaka City University School of Medicine.
出版信息
Gan To Kagaku Ryoho. 1987 Dec;14(12):3285-9.
We administered Bestrabucil, a benzoate ester of a complex of beta-estradiol and chlorambucil, continuously to six patients with breast cancer recurrent to local and regional lymph nodes, at a dose level of 200 mg/day. Of these six cases, one achieved CR, two PR, one MR, and two were NC. The drug was thus effective in 50% of the cases, with mild side effects. At the same time, since the concentration transfer to lymph nodes was satisfactory, Bestrabucil was thought to be an effective drug for the treatment of locally recurrent breast cancer.
我们对6例局部及区域淋巴结复发的乳腺癌患者持续给予倍他雌芥（β-雌二醇与苯丁酸氮芥复合物的苯甲酸酯），剂量为每日200毫克。在这6例患者中，1例达到完全缓解（CR），2例部分缓解（PR），1例病情稳定（MR），2例疾病无变化（NC）。因此，该药物在50%的病例中有效，且副作用轻微。同时，由于药物向淋巴结的浓度转移情况令人满意，倍他雌芥被认为是治疗局部复发性乳腺癌的有效药物。
Zotero 插件